On January 15, 2025, the US Drug Enforcement Administration (DEA) released a proposed rule entitled Special Registrations for Telemedicine and

“Basically, the farther the patients resided from an abortion facility, the more they were depending on the pills being mailed to them,” co-lead researcher Dr. Emily Godfrey, an OB/GYN and family doctor with the University of Washington, said in a news release.

A federal judge in Texas is allowing three other states to pursue a challenge seeking to restrict access to the abortion pill mifepristone nationwide

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her Endpoints News

A Texas judge has allowed three states to move forward with a legal challenge seeking to impose stricter rules on the abortion pill mifepristone, reigniting the battle over medication abortion access in the U.

Since the U.S. Supreme Court’s decision in 2022 to allow states to regulate abortion, support for expanded access to abortion pills has significantly increased, including among those living in states with abortion bans,

Hims & Hers Health Inc. (NYSE: HIMS), a telehealth company with a $6.1 billion valuation, has been a remarkable growth story, especially over the past year. The stock climbed an astounding 215% in 2024,

Discover why Hims & Hers Health is a top telehealth leader with impressive growth potential and a promising future for investors. Read more here.

The process of getting screened for cervical cancer is quite intimidating. It’s the once-a-year, sometimes life-changing treatment that involves the

The money brings Teal Health's total funding to $23 million as it prepares to launch the first FDA-approved cervical cancer product.

The Donald Trump-appointed federal judge in Texas who unilaterally ordered the FDA to revoke approval of a widely used abortion drug has now allowed Idaho, Kansas and Missouri to move forward with their own attempts to limit access to the drug.

An increased public interest and support for medication abortion following the federal Supreme Court ruling, particularly among marginalized groups, suggests a shift towards more accessible and autonomous models of abortion care.